EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer Summit 202622-24 January, Edinburgh
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PO3 | Metabolomic profiling of hepatocellular carcinoma patient sera prior to immune checkpoint inhibitor therapy | Henrike Salié |  Received |
 |
|||
| 1-PT | Outcomes by prior locoregional therapy use from the Phase 3 HIMALAYA study of tremelimumab + durvalumab in unresectable hepatocellular carcinoma | Bruno Sangro | Received |
|
|||
| 1-PO8 | Trends in historic aMAP scores in two Hepatocellular carcinoma (HCC) patient groups diagnosed within or outside an HCC surveillance programme | Avisnata Das | Received |
|
|||
| 1-PO7 | A novel cyclodextrin with improved safety profile for targeting hepatocellular carcinoma | Lara Stoffels | Received |
|
|||
| 1-PT | Cancer-Associated Fibroblasts in Hepatocellular Carcinoma Tumor Microenvironment and Prediction of Resistance to Atezolizumab + Bevacizumab Treatment | Guillem Cano-Segarra | Received |
|
|||
| 1-PO5 | Single-cell RNA sequencing reveals molecular concordance between circulating tumor cells and primary tumor nuclei in hepatocellular carcinoma | Monica Higuera | Received |
|
|||
| 1-PO9 | High LAG-3 and FGL1 expression as prognostic in hepatocellular carcinoma: a systematic review | Amanda Pordeus | Received |
|
|||
| 1-PO6 | Prognostic value of KRAS and TP53 mutations in patients with advanced biliary tract cancer treated with chemo-immunotherapy | Rita Balsano | Received |
|
|||
| 1-PO2 | Non-invasive tests for clinically significant portal hypertension in patients with compensated advanced chronic liver disease and hepatocellular carcinoma | Lorenz Balcar | Received |
|
|||
| 1-PO1 | Degradome implications in childhood liver cancer: Identifying CAND1 as a NEDDylation-regulated target in Hepatoblastoma | Leidy Estefanía Zapata-Pavas | Received |
|
|||
| 1-PO4 | When patients with cirrhosis and hepatocellular carcinoma meet the emergency room: clinical phenotypes and 28-day outcomes across acute-event clusters | Leonardo Stella | Received |
|
|||
| 2-PO6 | The multifaced role of post-operative serum phosphate level in the development of post-hepatectomy liver failure: a prospective preliminary analysis | Flavio Milana | Received |
|
|||
| 2-PO3 | Comparative diagnostic accuracy of hepatocellular carcinoma biomarkers: comprehensive meta-analysis with meta-regression. | Marco Vicardi | Received |
|
|||
| 2-PO9 | Use of Stereotactic Ablative Radiotherapy as a Locoregional Treatment Option for Hepatocellular Carcinoma – Outcomes at a Regional Centre | Bosire Oroko | Received |
|
|||
| 2-PT | The Hypoxic Niche Shapes Cancer-Associated Fibroblast Heterogeneity in Hepatocellular Carcinoma and Uncovers a Therapeutic Vulnerability | Jack Dishington | Received |
|
|||
| 2-PO2 | Cholangiocarcinoma in individuals with chronic liver disease is diagnosed earlier leading to better prognosis | Jone Narbaiza Martinez de Albeniz | Received |
|
|||
| 2-PT | Serum Procalcitonin: A New Tumor Biomarker for the Diagnosis and Monitoring of Fibrolamellar Hepatocellular Carcinoma | Jean Charles Nault | Received |
|
|||
| 2-PO7 | Identification of lncRNA signature involved in the effectiveness of tyrosine kinase inhibitors in cultured liver cancer cells | Ester Parras-Martínez | Received |
|
|||
| 2-PO1 | Pathologic versus radiologic response to neoadjuvant immunotherapy in hepatocellular carcinoma: results from the NeoHCC international consortium | Pasquale Lombardi | Received |
|
|||
| 2-PO5 | Photon-Counting Detector CT with Iodine Quantification: Improved distinction between bland and neoplastic portal vein thrombosis | Roman Prof. Dr. Kloeckner | Received |
|
|||
| 3-PT | Inflammation-driven IL-1ß–NOTCH signalling promotes pre-neoplastic transitions in biliary epithelium | Luke Boulter | Received |
|
|||
| 3-PO6 | Long-term outcomes and decompensation events in patients enrolled in hepatocellular carcinoma surveillance | William Rowley | Received |
|
|||
| 3-PO9 | Modelling of Patient-Specific Liver Vasculature and Sorafenib Pharmacokinetics in Hepatocellular Carcinoma | Mariia Myshkina | Received |
|
|||
| 3-PO8 | Identifying malnutrition and sarcopenia in patients with hepatocellular carcinoma – a tertiary liver centre experience | Devnandan Amor Chatterjee | Received |
|
|||
| 3-PO5 | Mitochondria-dependent STING activation enhances immune remodeling and cabozantinib response in hepatocellular carcinoma | Patricia Rider | Received |
|
|||
| 3-PO1 | The IL-7 rs16906115 single nucleotide polymorphism alters the risk for the development of treatment-related AEs in patients with HCC treated with immunotherapy | Lorenz Balcar | Received |
|
|||
| 3-PO2 | Platelet C3G restraints liver fibrosis and favours hepatocarcinoma development through the control of macrophage-liver cells crosstalk | Minerva Iniesta-González | Received |
|
|||
| 3-PO3 | Remaining chronic hepatitis C treatment gaps impact on the care cascade of HCV related hepatocellular carcinoma | Ericka Flores | Received |
|
|||
| 3-PT | Outcomes of cisplatin, gemcitabine, and durvalumab according to TOPAZ-1 study eligibility: a large global analysis in a real-world setting | Federica Lo Prinzi | Received |
|
|||
| 3-PO7 | Longitudinal evaluation of neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in patients with hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab. | Sara Ascari | Received |
|
|||
| 3-PO4 | Complementary Evaluation of Phase III Immunotherapy Trials in Advanced HCC using the Survival-Inferred Fragility Index | Dalbeni Andrea | Received |
|
|||
| 4-PO7 | Multidisciplinary clinic approach improves immunotherapy treatment outcomes in unresectable hepatocellular carcinoma: a multicentre retrospective study | Andrea Dalbeni | Received |
|
|||
| 4-PT | Metabolic rewiring by increased mitochondrial respiration drives immune evasion and brain metastasis in hepatocellular carcinoma | Naroa Goikoetxea-Usandizaga | Received |
|
|||
| 4-PO3 | HCC incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up: a retrospective multicentre study | Marta Guariglia | Received |
|
|||
| 4-PO5 | Predicting Decompensation in Advanced HCC on Immunotherapy: The ARTE Score | Lorenzo Canova | Received |
|
|||
| 4-PO4 | Glucagon-like peptide-1 receptor agonists for hepatocellular carcinoma prevention in type 2 diabetes: systematic review and meta-analysis. | Marco Vicardi | Received |
|
|||
| 4-PO2 | Beyond the Algorithm: Tumor-Board Determinants of Treatment-Stage Migration Across the BCLC stages (2020–2024) | Marta Fortuny | Received |
|
|||
| 4-PO1 | The influence of neutrophil migration on HCC in MASLD | Samuel Higginbotham | Received |
|
|||
| 4-PO8 | Cellular immunotherapies beyond checkpoint inhibitors in hepatocellular carcinoma: systematic review of chimeric antigen receptor T cell, T cell receptor engineered, and natural killer cell strategies | Jingying Chen | Received |
|
|||
| 4-PT | JAKaL: Phase Ib study of itacitinib, a selective JAK1 inhibitor, for the management of advanced stage hepatocellular cancer after failure of first line therapy. | Rohini Sharma | Received |
|
|||
| 4-PO6 | Trends in hepatocellular carcinoma (HCC) incidence and impact of hepatitis C antiviral therapy: A population-based subgroup analysis. | Bipneet Singh | Received |
|
|||
| 5-PT | In vitro identification of immunogenic tumoral antigens in advanced hepatocellular carcinoma reveals new opportunities for therapeutic applications | Frederik Peeters | Received |
|
|||
| 5-PO4 | Pilot study to explore the lived experience of Black patients diagnosed with Advanced Hepatocellular Carcinoma in a tertiary hepatocellular (HCC) centre in the United Kingdom (UK). | Eleni Petraki | Received |
|
|||
| 5-PT | An Artificial Intelligence-driven proteomic model to predict treatment response for systemic therapies in advanced hepatocellular carcinoma | Frederic Saltel | Received |
|
|||
| 5-PO5 | Humanised orthotopic tumours offer a physiologic model of human hepatocellular carcinoma and improved ex vivo therapeutic screening | Amy Collins | Received |
|
|||
| 5-PO3 | ESC and CARDIOSOR scores as easy tools to stratify cardiovascular risk in patients with HCC treated with atezolizumab/bevacizumab | Bernardo Stefanini | Received |
|
|||
| 5-PO7 | Clinical features and outcomes of patients with biliary tract cancer and a history of prior tumors: a retrospective cohort study from a tertiary cancer center | Martina Pino | Received |
|
|||
| 5-PO6 | A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma. | Ada Lerma -Clavero | Received |
|
|||
| 5-PO2 | GLUT3-Driven Metabolic Reprogramming Shapes Tumor Behavior and the Immune Landscape in Intrahepatic Cholangiocarcinoma | Michela Anna Polidoro | Received |
|
|||
| 5-PO8 | Outcomes of barcelona clinic liver cancer 2022 guideline-discordant escalation in hepatocellular carcinoma vary by a simple performance–liver function–tumour diameter phenotype | Hasan Sahin | Received |
|
|||
| 6-PO7 | HBsAg seroclearance in chronic hepatitis B is protective against hepatocellular carcinoma and decompensation | Zülal &304;stemihan | Received |
|
|||
| 6-PO6 | A data-driven precision medicine framework for primary liver cancer: insights from the Liver Cancer Collaborative | Louise Winteringham | Received |
|
|||
| 6-PO4 | Clinician-reported bias and stigma as barriers to HCC surveillance provision in the United Kingdom | Maria Qurashi | Received |
|
|||
| 6-PO2 | Metabolic Reprogramming in MASH-Related HCC: The Emerging Role of G6PD as a Biomarker and Target | Jessica Nurcis | Received |
|
|||
| 6-PT | a-Ketoglutarate–driven immune escape in hypoxic Metabolic Dysfunction-Associated Steatotic Liver Disease - related Hepatocellular Carcinoma: amino acid metabolism at the crossroads | Beatrice Foglia | Received |
|
|||
| 6-PO1 | Unraveling the role of PD-L1 in modulating the immune landscape of cholangiocarcinoma using a human-derived CCA-on-chip platform | Sofia Buzzi | Received |
|
|||
| 6-PT | Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma | Paula Olaizola | Received |
|
|||
| 6-PO5 | Cabozantinib in recurrent hepatocellular carcinoma after liver transplantation | Chiara Mazzarelli | Received |
|
|||
| 7-PO8 | Stereotactic Body Radiotherapy for the treatment of HCC: a single centre experience. | Alessandro Maver | Received |
|
|||
| 7-PO2 | HCC immune classification associated with pathological complete response to neoadjuvant therapy | Bertram Bengsch | Received |
|
|||
| 7-PO5 | MASLD-related hepatocellular carcinoma in cirrhotic and non-cirrhotic patients: a real-world analysis from the ITA.Li.Ca. cohort | Lucia Ragozzino | Received |
|
|||
| 7-PO1 | Sex differences in liver cancer mortality trends in the US: role of cancer type, etiology, and birth cohort | chiara suraci | Received |
|
|||
| 7-PO3 | Functional role of small RNA cluster 1 (smRC1) during hepatocarcinogenesis and angiogenesis | Francesca Pagani | Received |
|
|||
| 7-PO4 | GAAD score as a diagnostic and prognostic marker from cirrhosis to hepatocellular carcinoma | Silvia Cagnin | Received |
|
|||
| 7-PO7 | Performance of the GALAD score in hepatocellular carcinoma surveillance: a systematic review | Ana Carolina Leal | Received |
|
|||
| 7-PO6 | Prognostic value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in hepatocellular carcinoma: a study on relapse-free survival and overall survival after hepatectomy or transplantation | Konstantinos Arvanitakis | Received |
|
|||
| 8-PO5 | Validation and Modification of AJCC 8th Staging System for Distal Bile Duct Cancer | Won Ick Chang | Received |
|
|||
| 8-PO3 | Gaps remain in the cascade of hepatitis B care for people with HCC: a prospective cohort study | Jessica Howell | Received |
|
|||
| 8-PO1 | Platelets hijack neutrophils for pro-tumour polarisation in MASH-HCC | ERIK RAMON GIL | Received |
|
|||
| 8-PO6 | Aptamer-mediated blockade of HuR SUMOylation disrupts cholesterol metabolism and tumor progression in hepatocellular carcinoma | Patricia Pena-Sanfelix | Received |
|
|||
| 8-PO4 | Assessing Early HCC Recurrence After Liver Transplantation: The Predictive Value of 18F-FDG PET/CT and Microvascular invasion. | Lorenzo Canova | Received |
|
|||
| 8-PO2 | KLF15 acts as a tumor suppressor in cholangiocarcinoma by inhibiting cell proliferation, migration, and mitochondrial energetic activity | Mireia Tena Garitaonaindia | Received |
|
|||
| 8-PO7 | Gender disparities in hepatocellular carcinoma: implications for screening and treatment allocation. | Daniel Smith | Received |
|
|||
| 8-PO9 | Deep transfer learning-based discovery and validation of latent transforming growth factor binding protein 1 as a prognostic and druggable target in hepatocellular carcinoma | Esra Nalbat | Received |
|
|||
| 9-PO5 | Peripheral Lymphocytes in human liver hepatocellularcarcinoma: a newdruggable target as well as biomarker to help diagnosis and predictimmunotherapy response | Maria Elena Bellucco | Received |
|
|||
| 9-PO2 | Impact of deprivation on HCC patient outcomes at The Royal Free Hospital between 2014-2023 | Alexa Childs | Received |
|
|||
| 9-PO6 | Global Burden of Hepatitis B–Attributable Liver Cancer in West and Central Africa, 2000–2023: Trends in Incidence, Prevalence, and Mortality | &8234;Ekram Hasanin &8236;&8207; | Received |
|
|||
| 9-PO1 | Prognostic tissue biomarkers for cholangiocarcinoma after tumor resection: from literature review to multicenter international validation | Beatriz Coelho do Val | Received |
|
|||
| 9-PO8 | Predictors of HCC Recurrence Post-Treatment: considerations for future post treatment imaging surveillance | Tim Cross | Received |
|
|||
| 9-PO7 | How Liver Function Defines Real-World Outcomes with Atezolizumab–Bevacizumab in uHCC | Leonardo Stella | Received |
|
|||
| 9-PO9 | Association of the glucagon-like peptide 1 receptor with poor histological grading and metastatic potential of extrahepatic cholangiocarcinoma | Charupong Saengboonmee | Received |
|
|||
| 9-PO4 | p62/SQSTM1 expression is an independent marker of poor prognosis in a European hepatocellular carcinoma cohort | Theodoros Kozonis | Received |
|
|||
| 9-PO3 | Schlafen 5 potentiates HCC stemness through regulation of CD24 and enhancing glycolysis | Regina Lo | Received |
|
|||
| 10-PO1 | Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy | Mara Persano | Received |
|
|||
| 10-PO5 | Defining efficacy and dosimetric parameters for yttrium-90 radioembolization in hepatocellular carcinoma: a single-center experience with mRECIST and LI-RADS Radiation TRA in the era of immunotherapy | Maria Varela | Received |
|
|||
| 10-PO6 | Exploring the prognostic significance of miR-1973 and snoRNAs in hepatocellular carcinoma: a preliminary study | Venkata Ramana Mallela | Received |
|
|||
| 10-PO8 | Prospective assessment of the quality of multidisciplinary team meeting for the management of hepatocellular carcinoma. | Dr Amruthavarshini Nagabhushana | Received |
|
|||
| 10-PO4 | IMreal Cohort 6: Interim analysis of patients with unresectable hepatocellular carcinoma (HCC) treated with first-line atezolizumab + bevacizumab in the real-world setting of routine clinical practice | Nicolas Girard | Received |
|
|||
| 10-PO3 | Enhanced therapeutic efficacy of doxorubicin–atorvastatin combination therapy in hepatocellular carcinoma | MARIA KOPSIDA | Received |
|
|||
| 11-PO7 | JMJD2A epigenetically regulates hepatocellular carcinoma metabolism. | Pamela Calle-Mendoza | Received |
|
|||
| 11-PO5 | Plasma GDF15, Angiopoietin-2, and miRNAs as diagnostic tools in chronic liver disease progression to HCC | Elena Marchese | Received |
|
|||
| 11-PO3 | Exploring the bio-mechanics that underpin intrahepatic cholangiocarcinoma initiation. | Euan Brennan | Received |
|
|||
| 11-PO6 | Challenges in recruiting patients (pts) to clinical trials of systemic therapy in advanced hepatocellular carcinoma (HCC) | Christopher Graham | Received |
|
|||
| 11-PO1 | Targeting ferroptosis as a therapeutic vulnerability in preclinical models of cholangiocarcinoma | Jan David | Received |
|
|||
| 11-PO8 | Metagenomic Profiling of Gut Microbiome Signatures Across Liver Disease Stages and HCV-Related Hepatocellular Carcinoma in Egyptian Patients | Marwa Zahra | Received |
|
|||
| 11-PO2 | Multimodal artificial intelligence for predicting therapeutic decisions in hepatocellular carcinoma: integrating clinical reports and computed tomography imaging | Ciro Celsa | Received |
|
|||
| 12-PO1 | Prognostic role of adverse events in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab or pembrolizumab. | Linda Bartalini | Received |
|
|||
| 12-PO6 | Serum TGF-ß1 and IDO1 kinetics for the prediction of clinical outcomes among first-line immunotherapy treated patients with hepatocellular carcinoma | Orestis Sidiropoulos | Received |
|
|||
| 12-PO8 | Reprogramming of tumour-associated macrophages in liver affected by colorectal cancer metastases | Candela Cives-Losada | Received |
|
|||
| 12-PO2 | Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study | Miriam Longo | Received |
|
|||
| 12-PO3 | Bridging the gap between locoregional and systemic therapy: a systematic review on transarterial chemoembolization with immune checkpoint inhibitors in intermediate-stage hepatocellular carcinoma | Mariana Rocha | Received |
|
|||
| 12-PO5 | Combined hepatic arterial infusion chemotherapy, lenvatinib, anti-PD-1/PD-L1 antibody as conversion therapy for unresectable hepatocellular carcinoma: A 5-year real-world cohort study | Ruizhi Chang | Received |
|
|||
| 13-PO7 | Targeting the mdm2-p53 axis to restore tumour suppression and reprogramme the immune microenvironment in hepatocellular carcinoma patient-derived models and precision cut slices. | Keara Kirkness | Received |
|
|||
| 13-PO1 | Optimizing Hepatocellular Carcinoma (HCC) Patient Care: Global Study Unveils Best Practices in Three Critical Dimensions of Multidisciplinary Teams (MDTs) | Jörg Trojan | Received |
|
|||
| 13-PO3 | The impact of extrahepatic metastases in patients with hepatocellular carcinoma: A longitudinal analysis | PD Dr. Aline Mähringer-Kunz | Received |
|
|||
| 13-PO4 | Multimodal deep learning for early prediction of disease progression in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab | Ciro Celsa | Received |
|
|||
| 13-PO2 | Comparative performance of HCC risk scores in patients with cirrhosis in the Netherlands | Mohamed Moussa | Received |
|
|||
| 13-PO5 | A comparison of MAFLD and MASLD diagnostic criteria in estimating the risk of de novo hepatocellular carcinoma occurrence in HCV patients achieving sustained virological response | Fiammetta Di Nardo | Received |
|
|||
| 14-PO5 | Adding Artificial Intelligence support to the Multidisciplinary Oncologic Group-guided decision process is a valid strategy to optimize tailored therapies in the hepatocellular carcinoma management | Mario Romeo | Received |
|
|||
| 14-PO3 | Distinct cardiometabolic profiles drive divergent hepatocellular carcinoma risk trajectories in advanced fibrosis-affected metabolic dysfunction–associated steatotic liver disease (MASLD) patients | Mario Romeo | Received |
|
|||
| 14-PO2 | Elucidation of the molecular and histological architecture of liver yolk sac tumor and its patient-derived cell line reveals c-MYC–FOXM1 oncogenic dependencies | Darko Castven | Received |
|
|||
| 14-PO6 | Conversion surgery after immunotherapy in hepatocellular carcinoma: A French multicentric retrospective study | Giuliana Amaddeo | Received |
|
|||
| 14-PO7 | TROP2 expression correlates with poor survival and activation of cancer stem cell-like features in BTC | Paula Hoffmeister | Received |
|
|||
| 14-PO1 | Long-term survival and cure fraction in advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data | Jean Charles Nault | Received |
|
|||
| 14-PO8 | Post-transplant survival and causes of death in patients with hepatocellular carcinoma | Jan Paul Gundlach | Received |
|
|||
| 14-PO4 | Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Global Burden of Disease 2023 Study | &8234;Ekram Hasanin &8236;&8207; | Received |
|
|||
| 15-PO6 | Epidemiology and factors affecting survival of intrahepatic cholangiocarcinoma: A population-based study of 12,138 patients | Ker Shiong Tan | Received |
|
|||
| 15-PO8 | Real-world outcomes of first-line Durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancers : results from a French retrospective monocentric cohort | Nadia Darwane | Received |
|
|||
| 15-PO4 | Patient perspectives and barriers in HCC surveillance: insights to guide implementation of patient-centred pathways | Christopher Mysko | Received |
|
|||
| 15-PO2 | Patients´ first port of call: Primary care and HCC surveillance | Risha Dattani | Received |
|
|||
| 15-PO5 | Circulating reticulated platelets in hepatocellular carcinoma with and without liver cirrhosis | Pietro Guerra | Received |
|
|||
| 15-PO3 | Post-Cholecystectomy Syndrome affects Ultrasound Visualization in Non-Obese Viral-Related advanced chronic liver disease: implications of gallbladder removal for Li-RADS-based HCC surveillance | Marcello Dallio | Received |
|
|||
| 15-PO1 | PERK inhibition restricts tumor growth and disrupts GP73-mediated stromal activation in hepatocellular carcinoma (HCC) | Jaafar Khaled | Received |
|
|||
| 15-PO7 | Hypoxia-induced glycolytic shift reflects tumor aggressiveness in liver cancer spheroids | Nicolò Giglioli | Received |
|
|||
| 16-PO2 | Immune Rich, Prognosis Poor? Decoding TLS and CTNNB1 in hepatocellular carcinoma | Abdullah Malik | Received |
|
|||
| 16-PO1 | Longitudinal high-parameter immune cell phenotyping reveals distinctive polarisation of T-cell immunity associated with relapse following liver resection (LR) for hepatocellular carcinoma (HCC) | Eleonora Alimenti | Received |
|
|||
| 16-PO6 | 18F-Fluorodeoxyglucose positron emission tomography is a predictive factor of early response to atezolizumab-bevacizumab in patients with hepatocellular carcinoma | Maria Stella Franzè | Received |
|
|||
| 16-PO3 | Impact of expanded liver transplant criteria in the Brazilian population – Is there a better option than Milan Brazil criteria? | Aline Chagas | Received |
|
|||
| 16-PO7 | Involvement of the hERG1 potassium channel in cholangiocarcinoma cell biology | Giada Alla Viligiardi | Received |
|
|||
| 16-PO5 | The Role of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (HCC) with advanced basal tumour burden: from neoplastic portal invasion to extrahepatic metastasis, an Italian prospective study. | Filippo Cattazzo | Received |
|
|||
| 17-PO2 | The DeLIVER Programme: Benefits of live data reporting, quality assurance and analysis | James Robineau | Received |
|
|||
| 17-PO5 | Real-world compliance with hepatocellular carcinoma surveillance: experience from a regional service | William Rowley | Received |
|
|||
| 17-PO8 | Impact of Bridging Therapy Response on Dropout Rates in HCC Patients Awaiting Liver Transplantation | Aline Chagas | Received |
|
|||
| 17-PO3 | Interim clinical outcomes from a prospective cohort study of stereotactic body radiotherapy for hepatocellular carcinoma at a university hospital in Chile | Paula Rivera | Received |
|
|||
| 17-PO4 | Rol of PIVKA-II as a screening tool for HCC in a occidental cohort. | Maria Varela | Received |
|
|||
| 17-PO1 | Scavenger receptor MARCO acts as a modulator of the immunosuppressive tumor microenvironment and arises as a promising new therapeutic target for hepatocellular carcinoma | Maider Huici-Izagirre | Received |
|
|||
| 17-PO6 | Malnutrition assessed by Systemic Immune-inflammation Index predicts mortality in patients with hepatocellular carcinoma treated with immunotherapy | Lorenzo Argiento | Received |
|
|||
Liver Cancer Summit 2026
22-24 January, Edinburgh
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 22/01/2026 TO 22/01/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
